The SignalOS knowledge graph

Twelve biological networks, seventeen molecular nodes, and the research compounds that support each, mapped to the four-phase regeneration arc. This is the structured clinical model the engine reasons over.

Heart Signal→Mind Override→Allostatic Load→Cellular Danger Response→Communication Breakdown→Adaptive Symptoms→Disease Expression

Phase 1

Reduce Contraction

Phase 2

Restore Communication

Phase 3

Mitochondrial and Metabolic Expansion

Phase 4

Resilience and Longevity

ThreatPhase 1

Nervous-system threat and allostatic load. The contraction signal.

Nodes

cross-cutting

Peptides + compounds

DSIP 100 to 300 mcg nightlySelank 250 to 500 mcg dailyCBD 100 to 300 mg daily

NeurotransmitterPhase 1

Dopamine, serotonin, GABA balance. Mood, drive, calm.

Nodes

DopamineSerotoninGABA

Peptides + compounds

DSIP 100 to 300 mcg nightlySelank 250 to 500 mcg daily

InflammatoryPhase 2

NF-kB, TNF-alpha, IL-6 signaling. Chronic inflammatory tone.

Nodes

NF-kBTNF-alphaIL-6

Peptides + compounds

KPV 400 mcg daily (8 wk on / 4 wk off)

ImmunePhase 2

Immune regulation and tolerance.

Nodes

cross-cutting

Peptides + compounds

KPV 400 mcg daily (8 wk on / 4 wk off)BPC-157 500 mcg daily to twice dailyTB-500 5 mg weeklyThymosin Alpha-1 per practitioner

RepairPhase 2

Tissue and gut-lining repair, structural integrity.

Nodes

cross-cutting

Peptides + compounds

KPV 400 mcg daily (8 wk on / 4 wk off)BPC-157 500 mcg daily to twice dailyTB-500 5 mg weeklyGHK-Cu 2 to 5 mg daily or M/W/F

RedoxPhase 2

Oxidative balance, NRF2, vascular signaling.

Nodes

NRF2

Peptides + compounds

GHK-Cu 2 to 5 mg daily or M/W/F

EnergyPhase 3

ATP delivery and cellular energy availability.

Nodes

cross-cutting

Peptides + compounds

Ubiquinol 200 mg dailyMOTS-c 5 to 10 mg M/W/F fastedNAD+ 100 to 300 mg s.c. 2 to 3x weeklySS-31 5 to 10 mg daily or M/W/F

MitochondrialPhase 3

Mitochondrial output and biogenesis, PGC-1alpha, MOTS-c.

Nodes

NAD+PGC-1alpha

Peptides + compounds

Ubiquinol 200 mg dailyMOTS-c 5 to 10 mg M/W/F fastedNAD+ 100 to 300 mg s.c. 2 to 3x weeklySS-31 5 to 10 mg daily or M/W/F

MetabolicPhase 3

AMPK, insulin sensitivity, metabolic flexibility.

Nodes

AMPK

Peptides + compounds

MOTS-c 5 to 10 mg M/W/F fastedRetatrutide 0.25 to 0.5 mg weekly5-Amino-1MQ 5 to 10 mg dailyTesamorelin per practitioner

GrowthPhase 3

mTOR and growth/repair signaling balance.

Nodes

mTOR

Peptides + compounds

Tesamorelin per practitioner

MethylationPhase 2

MTHFR, COMT methylation capacity. Cross-cutting.

Nodes

MTHFRCOMT

Peptides + compounds

LongevityPhase 4

SIRT1, Klotho, NAD+, autophagy. Healthspan trajectory.

Nodes

SIRT1FOXOKlothoAutophagy

Peptides + compounds

GHK-Cu 2 to 5 mg daily or M/W/FNAD+ 100 to 300 mg s.c. 2 to 3x weekly5-Amino-1MQ 5 to 10 mg daily

Peptides referenced are research-use-only and not approved to diagnose, treat, cure, or prevent any disease. SignalOS is decision-support and education. It does not replace a licensed clinician. All protocols are reviewed and individualized by a practitioner.

Take the intake